Appendix F. Standard Terminology for D2d Publications and Presentations

This document will be updated as necessary, establishing standard terminology for all D2d publications and presentations to ensure consistent terminology is used when describing D2d.

- The visit called by D2d as the screening visit, will be called "**screening 1**" in D2d publications.
- The visit called by D2d as the baseline visit, will be called "**screening 2**" in D2d publications to distinguish it from baseline data, which only includes randomized participants.
- The term "**baseline**" refers to data collected prior to randomization (either at screening visit 1 or screening visit 2).
- "**Sex**" will be used to refer to the breakdown of males and females in the study, rather than the term "gender."
- **Funding acknowledgement** (confirm this statement is up-to-date prior to using)**:** Funding. The planning phase of D2d was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH through a multicenter clinical study implementation planning grant (U34) to Tufts Medical Center in Boston, MA (U34-DK-091958). Planning was also supported in part by the Intramural Research Program of the NIDDK. The conduct of D2d is supported by a U01 multicenter clinical study corporative agreement research grant from NIDDK, the Office of the NIH Director, and the NIH Office of Dietary Supplements (U01-DK-098245). Funding is also provided by the American Diabetes Association (1-14-D2d-01). Educational materials are provided by the National Diabetes Education Program.